Advertisement


Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Deborah Collyar: What's In It for Patients?

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement



Dec
08
Today In Oncology
Younger Postmenopausal Patients With Early-Stage Breast Cancer May Be Able to Safely Omit Adjuvant Radiotherapy
Patients With HR-Positive Breast Cancer May Use Fertility Preservation and Assisted Reproductive Technologies Without Increased Risk of Recurrence
Exercise May Boost Quality of Life for Patients With Metastatic Breast Cancer
Novel Targeted Therapies May Benefit Patients With Metastatic HR-Positive/HER2-Negative Breast Cancer
Risk Model May Accurately Predict Aromatase Inhibitor Nonadherence
View More 
Advertisement
© 2023 HSP News Service, L.L.C.
Designed by Harborside